RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes

Development of chemoresistance remains a major challenge in treating esophageal squamous cell carcinoma (ESCC) patients despite treatment advances. However, the role of RAC1 in chemoresistance of ESCC and the underlying mechanisms remain largely unknown. In this study, we found that higher levels of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Rui‐Jie, Zheng, Chun‐Wen, Gu, Jing‐E, Zhang, Hai‐Xia, Xie, Lei, Xu, Li‐Yan, Li, En‐Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717762/
https://www.ncbi.nlm.nih.gov/pubmed/31314174
http://dx.doi.org/10.1002/1878-0261.12548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717762/
https://www.ncbi.nlm.nih.gov/pubmed/31314174
http://dx.doi.org/10.1002/1878-0261.12548

Ejemplares similares